Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER × tanespimycin × Clear all

Phase

Phase 1 3 Phase 2 1

Status

Sponsor Class

NIH 12 INDUSTRY 6 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1

Interventions

Cisplatin 1028 Cyclophosphamide 968 Carboplatin 947 Radiotherapy 881 Bevacizumab 840 Gemcitabine 812 pembrolizumab 756 Paclitaxel 736 Docetaxel 732 Oxaliplatin 697 Capecitabine 640 Fluorouracil 561 Rituximab 557 Nivolumab 502 Dexamethasone 486 Etoposide 464 Doxorubicin 457 Irinotecan 442 Drug Therapy 393 Leucovorin 373 Cytarabine 341 Cetuximab 338 Lenalidomide 325 Trastuzumab 319 Pemetrexed 314 durvalumab 294 Filgrastim 287 Temozolomide 276 Prednisone 273 Methotrexate 270

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01228435 2017-12-04

IPI-504 in NSCLC Patients With ALK Translocations

Massachusetts General Hospital

Phase 2 Terminated

3 enrolled 5 charts

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡